Policy Recommendations for Strengthening the Accelerated Approval Program for Oncology Drugs
Memo: Delivered to the U.S. Food and Drug Administration (FDA)
Population Health
Policy
Patient Focused Drug Development: Methodologic and Other Challenges Related to Patient Experience Data
Comment: Submitted to the Food and Drug Administration and Department of Health and Human Services
Print:
On December 18, 2024, LDI Senior Fellow Sean Hennessy, PharmD, PhD submitted a comment in response to a Request for Comments from the U.S Food and Drug Administration and U.S. Department of Health and Human Services. The request sought input regarding methodological challenges related to data on patient experience.
As an expert in pharmacoepidemiology, the study of the health effects of drugs and other medical products in populations, Dr. Hennessy provides 10 suggestions for improving the use of patient experience data in patient focused drug development.
More on Policy at LDI
Estimated Overdose Deaths Due to the One Big Beautiful Bill Act
Research Memo: Delivered to House Speaker Mike Johnson and Majority Leader John Thune
Health Impacts of SNAP Provisions in the One Big Beautiful Bill Act
Research Memo: Delivered to House Speaker Mike Johnson and Majority Leader John Thune
Projected Mortality Impacts of the Budget Reconciliation Bill
Research Memo: Response to Request for Technical Assistance
Loss of Subsidized Drug Coverage and Mortality Following Medicaid Disenrollment: Translating our Findings and Implications for Medicaid Policy
Research Memo: Supplement to Response to Request for Technical Assistance
Medicaid’s Role in Health and the Health Care Landscape: Key Takeaways from LDI Researchers
Research Memo: Delivered to Staff of U.S. Senate Committee on Finance